|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI
|
|
2
|
Yu Y, Zhang Y and Zhang S: MicroRNA-92
regulates cervical tumorigenesis and its expression is upregulated
by human papillomavirus-16 E6 in cervical cancer cells. Oncol Lett.
6:468–474. 2013.PubMed/NCBI
|
|
3
|
Park TW, Fujiwara H and Wright TC:
Molecular biology of cervical cancer and its precursors. Cancer.
76((10 Suppl)): S1902–S1913. 1995.
|
|
4
|
Peiretti M, Zapardiel I, Zanagnolo V,
Landonia F, Morrowc CP and Maggionia A: Management of recurrent
cervical cancer: A review of the literature. Surg Oncol.
21:e59–e66. 2012.PubMed/NCBI
|
|
5
|
Li N, Cui T, Guo W, Wang D and Mao L:
MiR-155-5p accelerates the metastasis of cervical cancer cell via
targeting TP53INP1. Onco Targets Ther. 12:3181–3196.
2019.PubMed/NCBI
|
|
6
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20.
2013.PubMed/NCBI
|
|
7
|
Pardini B, De Maria D, Francavilla A, Di
Gaetano C, Ronco G and Naccarati A: MicroRNAs as markers of
progression in cervical cancer: A systematic review. BMC Cancer.
18:6962018.PubMed/NCBI
|
|
8
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005.PubMed/NCBI
|
|
9
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007.PubMed/NCBI
|
|
10
|
Takagi T and Iio AY: Decreased expression
of microRNA-143 and −145 in human gastric cancers. Oncology.
77:12–21. 2009.PubMed/NCBI
|
|
11
|
Liu X, Sempere LF, Galimberti F,
Freemantle SJ, Black C, Dragnev KH, Ma Y, Fiering S, Memoli V, Li
H, et al: Uncovering growth-suppressive MicroRNAs in lung cancer.
Clin Cancer Res. 15:1177–1183. 2009.PubMed/NCBI
|
|
12
|
Li C, Xu N, Li YQ, Wang Y and Zhu ZT:
Inhibition of SW620 human colon cancer cells by upregulating mi
RNA-145. World J Gastroenterol. 22:2771–2778. 2016.PubMed/NCBI
|
|
13
|
Zhang J, Wang L, Li B, Huo M, Mu MU, Liu J
and Han J: miR-145 downregulates the expression of cyclin-dependent
kinase 6 in human cervical carcinoma cells. Ther Med. 8:591–594.
2014.
|
|
14
|
Hashimoto Y, Skacel M and Adams JC: Roles
of fascin in human carcinoma motility and signaling: Prospects for
a novel biomarker? Int J Biochem Cell Biol. 37:1787–804.
2005.PubMed/NCBI
|
|
15
|
Li A, Dawson JC, Forero-Vargas M, Spence
HJ, Yu XZ, König I, Anderson K and Machesky LM: The actin-bundling
protein fascin stabilizes actin in invadopodia and potentiates
protrusive invasion. Curr Biol. 20:339–345. 2010.PubMed/NCBI
|
|
16
|
Liu R, Liao J, Yang M, Sheng J, Yang H,
Wang Y, Pan E, Guo W, Pu Y, Kim SJ and Yin L: The cluster of
miR-143 and miR-145 affects the risk for esophageal squamous cell
carcinoma through co-regulating fascin homolog 1. PLoS One.
7:e339872012.PubMed/NCBI
|
|
17
|
Zhang M, Dong BB, Lu M, Zheng MJ, Chen H,
Ding JZ, Xu AM and Xu YH: miR-429 functions as a tumor suppressor
by targeting FSCN1 in gastric cancer cells. Onco Targets Ther.
9:1123–1133. 2016.PubMed/NCBI
|
|
18
|
Li J, Lu J, Ye Z, Han X, Zheng X, Hou H,
Chen W, Li X and Zhao L: 20(S)-Rg3 blocked epithelial-mesenchymal
transition through DNMT3A/miR-145/FSCN1 in ovarian cancer.
Oncotarget. 8:53375–53386. 2017.PubMed/NCBI
|
|
19
|
Chen JJ, Cai WY, Liu XW, Luo QC, Chen G,
Huang WF, Li N, Cai JC and Yang CF: Reverse correlation between
MicroRNA-145 and FSCN1 affecting gastric cancer migration and
invasion. PLoS One. 10:e0126902015.
|
|
20
|
Ma L and Li LL: miR-145 Contributes to the
progression of cervical carcinoma by directly regulating FSCN1.
Cell Transplant. 28:1299–1305. 2019.PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI
|
|
22
|
Bartel DP: MicroRNAs genomics, biogenesis,
mechanism, and function. Cell. 116:281–297. 2004.PubMed/NCBI
|
|
23
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009.PubMed/NCBI
|
|
24
|
Slattery ML, Herrick JS, Mullany LE,
Valeri N, Stevens J, Caan BJ, Samowitz W and Wolff RK: An
evaluation and replication of miRNAs with disease stage and
colorectal cancer-specific mortality. Int J Cancer. 137:428–438.
2015.PubMed/NCBI
|
|
25
|
Gao W, Zhang C, Li W, Li H, Sang J, Zhao
Q, Bo Y, Luo H, Zheng X, Lu Y, et al: Promoter
methylation-regulated miR-145-5p inhibits laryngeal squamous cell
carcinoma progression by targeting FSCN1. Mol Ther. 27:365–379.
2019.PubMed/NCBI
|
|
26
|
Stewart CJ, Crook M and Loi S: Fascin
expression in endocervical neoplasia: Correlation with tumour
morphology and growth pattern. J Clin Pathol. 65:213–217.
2012.PubMed/NCBI
|
|
27
|
Koay MH, Crook M and Stewart CJ: Fascin
expression in cervical normal squamous epithelium, cervical
intraepithelial neoplasia, and superficially invasive (stage IA1)
squamous carcinoma of the cervix. Pathology. 46:433–438. 2018.
|
|
28
|
Zhao D, Zhang T, Hou XM and Ling XL:
Knockdown of fascin-1 expression suppresses cell migration and
invasion of non-small cell lung cancer by regulating the MAPK
pathway. Biochem Biophys Res Commun. 497:694–699. 2018.PubMed/NCBI
|
|
29
|
Yang J, Zhang N, Gao R, Zhu Y, Zhang Z, Xu
X, Wang J, Li Z, Liu X, Li Z, et al: TGF-β1 induced fascin1
expression facilitates the migration and invasion of kidney
carcinoma cells through ERK and JNK signaling pathways. Biochem
Biophys Res Commun. 501:913–919. 2018.PubMed/NCBI
|
|
30
|
Zhang M, Zhao Z, Duan X, Chen P, Peng Z
and Qiu H: FSCN1 predicts survival and is regulated by a
PI3K-dependent mechanism in renal cell carcinoma. J Cell Physiol.
233:4748–4758. 2018.PubMed/NCBI
|
